Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care
GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This software integration provides endocrinology practices that partner with SweetSpot the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients using Eversense 365, the world's first and only One Year CGM.
SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services. SweetSpot's virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients on treatment plan assessment and changes. By developing an integration with Eversense 365, SweetSpot can work alongside practices to act on this unique system's CGM data in between patients' scheduled appointments, allowing for more personalized support. These regular data reviews help ensure patients get timely treatment adjustments, keeping them better connected to their diabetes care team year-round with a goal of improving glycemic control. Practices can also unlock new opportunities through SweetSpot's automated capture of reimbursable care events, making partnering with SweetSpot both clinically impactful and operationally efficient.
Eversense 365 is developed by Senseonics and brought to patients by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE: 6523). As the only implantable CGM available, it offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision-making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM.
Dr Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, said: 'SweetSpot removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care. Our dedicated team is passionate about transforming how diabetes is managed – and making sure that no opportunities are missed to use the rich data from CGMs for improved care. This integration with Eversense reinforces SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for our partners by integrating more CGM options, such as the only implantable CGM on the market.'
Mukul Jain, Chief Operating Officer of Senseonics, added: 'We are pleased to enable integration with SweetSpot to help healthcare providers using the software platform to optimize care for patients using Eversense 365. Our CGM offers a completely fresh approach to diabetes management by collecting a whole year of glucose data with just one CGM. We continue to focus on bringing Eversense 365 to more people across the country and are excited to see how integrations like this can further enhance our compelling offering for patients and healthcare providers.'
Dr. Jacob Vadakekalam of the Diabetes & Glandular Disease (DGD) Clinic in San Antonio, Texas, added: 'As a doctor committed to providing the best care possible, I am pleased about the partnership between SweetSpot and Eversense. This collaboration represents a step forward in healthcare integration, and I believe it will have a positive impact on diabetes management for my patients here at the Diabetes & Glandular Disease Clinic and in turn minimizing future hospitalizations.'
Notes for Editors
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see www.eversensediabetes.com/safety-info/.
A media kit for Eversense 365, including images, logos and further information, can be accessed at www.ascensia.com/media/eversense365-media-kit/
About SweetSpot
SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care. SweetSpot combines a centralized software platform for managing diabetes device data, such as data from CGMs and insulin pumps, with wrap-around clinical support services. SweetSpot's virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients to facilitate treatment plan changes. By actively managing and remotely reviewing CGM data between patient visits, we ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes. Additionally, SweetSpot's automated capture of reimbursable care events optimizes CPT code utilization, unlocking new revenue streams for practices and making our partnerships both clinically effective and financially profitable.For more information, visit www.sweetspot.health.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com
Forward Looking Statements
Any statements in this press release about the expectations regarding potential impact on patients' and providers' experience and outcomes, and other statements containing the words "believe," 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.
Ascensia Communications Contact:
Tim StamperFTI ConsultingTim.Stamper@fticonsulting.com
Senseonics Investor Contact
Jeremy FefferLifeSci Advisorsinvestors@senseonics.com
SweetSpot Communications Contact:
Joelle FredmanDirector of Marketingjfredman@aegisdigitalhealth.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Tronox Holdings PLC (TROX) Q2 2025 Earnings Call Highlights: Strategic Cost Management Amid ...
Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tronox Holdings PLC (NYSE:TROX) is executing a disciplined strategy to manage the downturn and optimize earnings and cash flow. The cost improvement program is progressing ahead of plan, with expectations to deliver $125 to $175 million in sustainable run rate savings by the end of 2026. Early sales momentum in India is encouraging, aided by the Australia-India Free Trade Agreement and duties against Chinese imports. The company has entered into an inventory financing program, providing an additional $50 million of liquidity. Tronox Holdings PLC (NYSE:TROX) is proactively managing its balance sheet to bolster liquidity and maintain financial flexibility. Negative Points The second quarter was impacted by weaker demand across most end markets, resulting in an 11% year-over-year decrease in volumes. Revenue decreased by 11% versus the prior year, driven by lower sales volumes and unfavorable zircon pricing. The company reported a net loss of $84 million, including $39 million of restructuring and other charges. Adjusted EBITDA declined 42% year-over-year due to higher production costs, unfavorable commercial impacts, and higher freight costs. The dividend was reduced by 60% to align with the current macro environment, reflecting prolonged market weakness. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with TROX. Q: What are the key drivers that will determine whether Tronox meets the higher or lower end of its EBITDA guidance range of $410 to $460 million for 2025? A: John Romano, CEO, explained that the primary factors are volume and price. The company does not anticipate a significant increase in volume, but expects some targeted gains in India. There is competitive activity in Europe affecting pricing, and some price erosion is expected. The guidance is largely dependent on these pricing and volume dynamics. Q: Can you provide an update on Tronox's rare earth activities? A: John Romano, CEO, stated that Tronox is continuing to work on rare earth opportunities. While there is no immediate capital allocation for this, the company is developing opportunities for sales of other products, including rare earth elements, in the second half of the year. Q: What factors contributed to the 2% sequential decline in TIO2 volumes, and how much was due to market share loss? A: John Romano, CEO, noted that the decline was largely due to a muted coating season in North America, not market share loss. In Europe, Middle East, and Africa, there was a volume decline due to a less robust market and competitive activity. Asia Pacific saw growth driven by India, while Latin America was flat but expected to improve later in the year. Q: What are the implications of the new reductions to Tronox's CapEx forecast, and what might be sacrificed in terms of future efficiencies? A: John Serveal, CFO, explained that the reductions are primarily in discretionary areas, not affecting strategic mining investments in South Africa. The focus is on managing cash while maintaining critical investments for safe and reliable operations. Q: How is Tronox managing its free cash flow and working capital, especially in relation to production adjustments? A: John Romano, CEO, stated that Tronox is matching production to demand, primarily on the TIO2 side, while also considering adjustments in mining. The company is using its vertical integration to balance cash and EBITDA, with expectations to generate cash from working capital in the second half of the year. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Upturn
30 minutes ago
- Business Upturn
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States. We are proud to share that we have been included in the Medicare fee schedule, allowing us to offer national Medicare coverage along with our new partnerships with CareSource and HealthPartners. The SmartVascular Dx test provides a significant clinical advantage by accurately detecting vascular inflammation, a crucial factor in assessing cardiovascular risk. In a healthcare landscape increasingly focused on preventive strategies, this test supports early intervention, aligning seamlessly with the commitment to proactive healthcare in the region. We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement timely interventions, ultimately saving lives and improving health outcomes. Furthermore, we are excited to announce our partnership with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
30 minutes ago
- Business Upturn
FLR BREAKING INVESTIGATION: BFA Law Announces an Investigation into Fluor Corporation after Stock Plummets over 30% on Infrastructure Delays – Contact BFA Law if You Lost Money
By GlobeNewswire Published on August 2, 2025, 00:37 IST NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Fluor Corporation (NYSE: FLR) for potential violations of the federal securities laws. If you invested in Fluor, you are encouraged to obtain additional information by visiting: Why Is Fluor being Investigated? Fluor is a global professional services firm that provides engineering, procurement and construction, fabrication and modularization, and project management services. The Company has three principal segments: Urban Solutions, Energy Solutions and Mission Solutions. Its Urban Solutions segment includes infrastructure teams that provide a broad range of services, including consulting, design, planning, financial structuring, engineering, construction and operation and maintenance services. During the relevant period, the Company touted the strong productivity across its infrastructure portfolio. In truth, several of Fluor's infrastructure projects experienced undisclosed design errors, delays, and price escalation that significantly impacted its business. The Stock Declines as the Truth Is Revealed On August 1, 2025, before market hours, Fluor reported its fiscal Q2 2025 financial results and held an earnings call. The Company announced disappointing earnings and revealed 'a $54 million net impact of cost growth and expected recoveries on three infrastructure projects, due to subcontractor design errors, the related schedule impacts, and price escalation.' The Company also announced, 'a shift in expected capital spending from some clients.' On this news, the price of Fluor stock fell more than 30% during trading on August 1, 2025. Click here for more information: What Can You Do? If you invested in Fluor you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA , The Legal 500 , and ISS SCAS , and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal , among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon , 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
